Pfizer Inc. (NYSE:PFE) Receives Average Recommendation of “Hold” from Analysts

Pfizer Inc. (NYSE:PFE) has earned a consensus rating of “Hold” from the sixteen brokerages that are currently covering the stock, Marketbeat reports. Ten equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $36.33.

Several analysts have recently issued reports on the company. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Guggenheim began coverage on Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Finally, TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research report on Thursday, January 4th.

Hedge Funds Weigh In On Pfizer

Large investors have recently added to or reduced their stakes in the company. Briaud Financial Planning Inc acquired a new position in shares of Pfizer in the 3rd quarter worth approximately $30,000. Mizuho Securities Co. Ltd. acquired a new position in shares of Pfizer in the 3rd quarter worth approximately $34,000. VisionPoint Advisory Group LLC raised its holdings in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares in the last quarter. GoalVest Advisory LLC raised its holdings in shares of Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares in the last quarter. Finally, Creekmur Asset Management LLC acquired a new position in shares of Pfizer in the 4th quarter worth approximately $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

PFE opened at $25.40 on Friday. The company has a market cap of $143.83 billion, a PE ratio of 70.56, a price-to-earnings-growth ratio of 1.14 and a beta of 0.61. The stock has a 50-day moving average of $26.96 and a 200-day moving average of $28.39. Pfizer has a 52-week low of $25.20 and a 52-week high of $40.37. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. The company had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm’s revenue was down 41.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.14 EPS. As a group, equities research analysts forecast that Pfizer will post 2.24 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be issued a $0.42 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 6.61%. Pfizer’s dividend payout ratio (DPR) is 466.67%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.